Capricor Therapeutics, Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company that develops transformative cell and exosome-based therapeutics for the treatment of Duchenne muscular dystrophy and other rare diseases with high unmet medical needs. Founded in 2005 and headquartered in San Diego, California, the company focuses on allogeneic cardiosphere-derived cells and engineered exosomes, targeting primary markets in the United States, Japan, and Europe through strategic partnerships. Its lead product candidate, deramiocel (also known as CAP-1002), comprises cardiosphere-derived cells that provide immunomodulatory, anti-fibrotic, anti-inflammatory, and regenerative effects via exosome-mediated mechanisms, including microRNAs that alter gene expression to reduce inflammation and promote tissue repair in dystrophinopathies; deramiocel has completed the Phase 3 HOPE-3 trial, demonstrating statistically significant improvements in skeletal and cardiac function, building on durable benefits observed in the HOPE-2 trial and its over 48-month open-label extension. The company advances a proprietary StealthX exosome platform for precision-engineered therapeutics, including targeted delivery of RNA, proteins, small molecules, and vaccines; this encompasses preclinical and early-stage programs such as an NIAID-funded Phase 1 exosome-based vaccine candidate for infectious diseases with topline data expected in early 2026, alongside CAP-2003 for DMD and broader applications in inflammatory and regenerative medicine. Capricor maintains license agreements with institutions including Johns Hopkins University, University of Rome, Cedars-Sinai Medical Center, and Life Technologies to support its cell and exosome technologies. In recent developments, Capricor announced positive topline results from the pivotal Phase 3 HOPE-3 study of deramiocel in December 2025, prompting plans for a Biologics License Application resubmission to the FDA by year-end incorporating this data to address prior manufacturing observations from a Complete Response Letter; the company expanded its partnership with Nippon Shinyaku Co., Ltd. and NS Pharma, Inc. in 2024 to include exclusive commercialization and distribution rights for deramiocel in Europe alongside the existing U.S. and Japan agreements, which provide upfront payments, development and sales milestones up to approximately $89 million, and double-digit royalties. Capricor reports a cash position of approximately $99 million as of Q3 2025, sufficient to fund operations into late 2026 amid commercial launch preparations for potential 2026 market introduction and ongoing exosome platform advancement.
Company News
CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28 Deadline
Kaplan Fox Notifies Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the Lead Plaintiff Deadline on September 28, 2026
CAPR DEADLINE NOTICE: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026
CAPR Stock Drop: Capricor Therapeutics Faces Securities Fraud Class Action Over Clinical Data; BFA Law Reminds Investors of September 28 Deadline
CAPR DEADLINE NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - CAPR
CAPR Stock Alert: Capricor Therapeutics, Inc. Reports Q2 Earnings Amid Ongoing Securities Class Action Lawsuit - Hagens Berman
CAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
Kaplan Fox Reminds Investors of a Deadline for a Securities Fraud Class Action Lawsuit Against Capricor Therapeutics, Inc. (CAPR) on September 28, 2026
CAPR Investor Alert: Capricor Therapeutics, Inc. Securities Class Action Notice - Contact SueWallSt
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Capricor Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - CAPR
CAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - September 28, 2026 Deadline
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
CAPR DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Capricor Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - CAPR
Capricor Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Capricor Therapeutics, Inc. - CAPR
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Hagens Berman Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to FDA Review Extension for Deramiocel Amid Ongoing Securities Class Action and September 28 Lead Plaintiff Deadline
CAPR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026